Observations placeholder
Amevive and Alefacept
Identifier
017986
Type of Spiritual Experience
Number of hallucinations: 1
Background
A description of the experience
Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion. This drug was never approved for the European drug market.
Alefacept is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation. It is also being studied in the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma.
On Oct, 8, 2015: 3,569 people reported to have side effects when taking Amevive. Among them, 1 people (0.03%) has Hallucination.
Time on Amevive when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Oct, 2, 2015: 3,569 people reported to have side effects when taking Amevive. Among them, 83 people (2.33%) have Death.
Time on Amevive when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 39.13% | 56.52% | 0.00% | 4.35% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Amevive :
| Female | Male | |
| Death | 61.54% | 38.46% |
Age of people who have Death when taking Amevive :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.56% | 16.39% | 77.05% |